Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders

被引:0
|
作者
Freedman, Kenneth [1 ]
Nathanson, Jay [2 ]
机构
[1] Tufts Univ, Sch Med, Lemuel Shattuck Hosp, Boston, MA 02130 USA
[2] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA
关键词
buprenorphine; compliance; depression; drug addiction; hepatitis C; IFN-alpha; methadone; psychiatric; substance abuse; INJECTION-DRUG USERS; DIRECTLY OBSERVED THERAPY; VIRUS-INFECTION; MAINTENANCE TREATMENT; METHADONE; OUTCOMES; HIV; MANAGEMENT; RIBAVIRIN; ALPHA;
D O I
10.1586/ERI.09.1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Hepatitis C infection in patients with mental illness and drug addiction is highly prevalent and infrequently treated. Over the past 5 years, a wealth of studies specifically focused on these groups have demonstrated comparable rates of sustained virological response, compliance and adverse events. Optimization of psychotropic and opioid-replacement therapy with integrated psychiatric/addiction treatment prior to and during IFN-alpha initiation produces optimal results. Experience in treating these populations demonstrates clinical outcomes comparable with those without these comorbidities. Patients with mental illness and drug addiction should have routine screening and treatment for HCV infection to prevent associated morbidity and mortality.
引用
收藏
页码:363 / 376
页数:14
相关论文
共 50 条
  • [1] Interferon-based treatment of chronic hepatitis C
    Souvignet, Claude
    Lejeune, Olivier
    Trepo, Christian
    BIOCHIMIE, 2007, 89 (6-7) : 894 - 898
  • [2] "Shotgunning" in a Population of Patients with Severe Mental Illness and Comorbid Substance Use Disorders
    Welsh, Christopher
    Goldberg, Richard
    Tapscott, Stephanie
    Medoff, Deborah
    Rosenberg, Stanley
    Dixon, Lisa
    AMERICAN JOURNAL ON ADDICTIONS, 2012, 21 (02) : 120 - 125
  • [3] Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment
    Kelly, Erin M.
    Corace, Kimberly
    Emery, Joel
    Cooper, Curtis L.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (07) : 811 - 816
  • [4] Treating substance use disorders in patients with hepatitis C
    Cucciare, Michael A.
    Cheung, Ramsey C.
    Rongey, Catherine
    ADDICTION, 2015, 110 (07) : 1057 - 1059
  • [5] Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders
    Rosenberg, SD
    Drake, RE
    Brunette, MF
    Wolford, GL
    Marsh, BJ
    AIDS, 2005, 19 : S26 - S33
  • [6] Efficacy of Peg-Interferon Based Treatment in Patients with Hepatitis C Refractory to Previous Conventional Interferon-Based Treatment
    Shaikh, Samiullah
    Devrajani, Bikha Ram
    Kalhoro, Musarat
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2012, 22 (10): : 635 - 639
  • [7] A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use
    Sockalingam, Sanjeev
    Blank, Diana
    Banga, Claire Ann
    Mason, Kate
    Dodd, Zoe
    Powis, Jeff
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (12) : 1377 - 1384
  • [8] Treatment Rate and Factors Related to Interferon-based Treatment Initiation for Chronic Hepatitis C in South Korea
    Lee, Sang Soo
    Jeong, Sook-Hyang
    Jang, Eun Sun
    Kim, Young Seok
    Lee, Youn Jae
    Jung, Eun Uk
    Kim, In Hee
    Bae, Si Hyun
    Lee, Han Chu
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (02) : 275 - 281
  • [9] Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues
    Bonner, Jason E.
    Barritt, A. Sidney
    Fried, Michael W.
    Evon, Donna M.
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (06) : 1469 - 1474
  • [10] Inclusion in the cancer patient pathway among cancer patients with and without pre-existing mental or substance use disorders: a nationwide register-based study
    Ina H. Heiberg
    Lise Balteskard
    Bjarne K. Jacobsen
    Jørgen G. Bramness
    Ragnar Nesvåg
    Kjell Magne Tveit
    Anne Høye
    BMC Public Health, 25 (1)